FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
A new website created by the Centers for Disease Control offers resources for pharmacists to help patients quit smoking.
Study finds higher risk of cardiovascular and cerebrovascular disease in COPD patients, suggests spread of inflammation may be a factor.
The number of measles cases reported to the Centers for Disease Control and Prevention during the first 5 months of 2014 is the highest reported for that period since 1994.
Latest Issues
$auto_registration$